SciencemRNA Cancer Vaccine Halts Melanoma in Phase 3 TrialModerna and Merck's personalized mRNA vaccine stopped melanoma returning post-surgery in a landmark Phase 3 trial of 1,000 high-risk patients.
TechnologymRNA Cancer Vaccine Cuts Melanoma Recurrence by 49% After Five YearsNew five-year data from the KEYNOTE-942 trial shows Moderna's personalized mRNA vaccine intismeran, paired with Keytruda, nearly halves the risk of melanoma returning after surgery.
